AYTU · Aytu Biopharma, Inc
Market Cap
$23.91M
Shares
10.87M
Volume · Oct 5
63.92K
Avg daily vol (3M)
35.5K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.04
Open$2.05
Day$2.04–2.15
52W close$1.94–2.90
Avg vol 30d42K
Short int312K · 2.9% float · 12.9d
Short vol66%
Last earningsSep 22, 2026
DataJan 2020–Oct 2026
Filing10-K · Sep 22
Up next
Next earnings call
Dec 22, 2026
Est · unconfirmed
· in 11 wks
filed Sep 22, 2026
call held Sep 22, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$57.57M
Trailing 12 months
Net income (TTM)
−$14.25M
Trailing 12 months
Revenue growth YoY
+6.4%
Year over year
Operating margin
-14.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
13.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.1%
Year over year · more shares
Price change (1Y)
+5.1%
Trailing year
Short interest
2.9%
Latest settlement · 12.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
−8%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−20%
trailing
YTD return
−22%
this year
Relative strength
−32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.87% of float · ▼ -6.8% MoM · 12.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
38 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+277%
Y/Y
Gross margin
133%
contracting
EPS growth
+93%
Y/Y
Free cash flow
$3.3M
Balance sheet
$15.4M
net cash
Quant / Vol
risk profile
Volatility
48%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 22, 2026
fiscal 2027
Operating expenses on a GAAP basis
GAAP
Initiated
$49M – $54M
Total cash-based operating expenses
Initiated
$45M – $49M
Sales and marketing expense
Initiated
up to $6M
fourth quarter of fiscal 2027
Consolidated gross margin
Initiated
66% – 67%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.87% of float · ▼ -6.8% MoM · 12.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
38 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 10%
Range high $3
vs 200-day avg -14%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA - non-GAAP non-GAAP | $490K | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss - GAAP -15K
+383K Interest expense
+11K Income tax expense
+1.12M Depreciation and amortization
+146K Stock-based compensation expense
-173K Other expense (income), net
-983K Derivative warrant liabilities loss (gain)
+0K Non-recurring legal fees
+0K Restructuring costs
+0K Impairment expense
+0K Pipeline research and development costs
+0K Net (income) loss from discontinued operations, net of tax
= Adjusted EBITDA - non-GAAP 490K
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AYTU
this stock
Aytu Biopharma, Inc
|
$23.91M | -21.5% | +277.5% | — | 2.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AYTU | -6.0% | -7.7% | -20.3% | -4.7% | -21.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -7.2% | -8.3% | -31.9% | -6.3% | -35.2% |